AMGN EBITDA | Amgen Inc.

Amgen Inc. (AMGN) EBITDA

2026-06-30: Basis Reported; EBITDA $4.63B*; Operating income $3.51B; Depreciation and amortization $1.11B*.
2026-03-31: Basis Reported; EBITDA $3.78B; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $3.85B; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $3.83B*; Operating income $2.53B; Depreciation and amortization $1.31B*.

Complete source-backed ebitda history.

Available history: 2007-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	$4.63B*	$3.51B	$1.11B*	$10.05B	46.01%*	$513.00M*	$4.00B*	$2.81B	(m)	$1.75B	$393.00M
2026-03-31	Reported	$3.78B	(m)	(m)	(m)	43.88%	$712.00M	$2.19B	$2.74B	(m)	$1.60B	$265.00M
2025-12-31	Reported	$3.85B	(m)	(m)	(m)	39.04%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$3.83B*	$2.53B	$1.31B*	$9.56B	40.11%*	$436.00M*	$4.68B*	$3.08B	(m)	$1.72B	$705.00M
2025-06-30	Reported	$4.00B*	$2.66B	$1.34B*	$9.18B	43.55%*	$369.00M*	$2.28B*	$3.01B	(m)	$1.69B	$136.00M
2025-03-31	Reported	$2.57B	(m)	(m)	(m)	31.48%	$411.00M	$1.39B	$2.97B	(m)	$1.69B	$243.00M
2024-12-31	Reported	$3.71B	(m)	(m)	(m)	40.81%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	$3.44B*	$2.05B	$1.40B*	$8.50B	40.49%*	$257.00M*	$3.57B*	$3.31B	(m)	$1.63B	$271.00M
2024-06-30	Reported	$3.31B*	$1.91B	$1.40B*	$8.39B	39.45%*	$238.00M*	$2.46B*	$3.24B	(m)	$1.78B	$48.00M
2024-03-31	Reported	$2.39B	(m)	(m)	(m)	32.09%	$230.00M	$689.00M	$3.20B	(m)	$1.81B	$45.00M
2023-12-31	Reported	$2.65B	(m)	(m)	(m)	32.35%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	$2.92B*	$2.02B	$895.00M*	$6.90B	42.24%*	$248.00M*	$2.76B*	$1.81B	(m)	$1.35B	$217.00M
2023-06-30	Reported	$3.58B*	$2.68B	$896.00M*	$6.99B	51.25%*	$271.00M*	$4.11B*	$1.81B	(m)	$1.29B	$235.00M
2023-03-31	Reported	$2.82B	(m)	(m)	(m)	46.21%	$344.00M	$1.06B	$1.72B	(m)	$1.26B	$601.00M
2022-12-31	Reported	$3.14B	(m)	(m)	(m)	45.93%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	$3.50B*	$2.66B	$837.00M*	$6.65B	52.57%*	$160.00M*	$2.98B*	$1.59B	(m)	$1.29B	$249.00M
2022-06-30	Reported	$3.00B*	$2.18B	$828.00M*	$6.59B	45.56%*	$246.00M*	$1.93B*	$1.51B	(m)	$1.33B	$214.00M
2022-03-31	Reported	$3.34B	(m)	(m)	(m)	53.56%	$190.00M	$2.16B	$1.56B	(m)	$1.23B	$199.00M
2021-12-31	Reported	$3.16B	(m)	(m)	(m)	46.10%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	$3.23B*	$2.38B	$850.00M*	$6.71B	48.14%*	$242.00M*	$2.42B*	$1.61B	(m)	$1.30B	$271.00M
2021-06-30	Reported	$1.68B*	$828.00M	$855.00M*	$6.53B	25.79%*	$185.00M*	$1.93B*	$1.64B	(m)	$1.38B	$94.00M
2021-03-31	Reported	$2.97B	(m)	(m)	(m)	50.33%	$166.00M	$2.10B	$1.49B	(m)	$1.25B	$211.00M
2020-12-31	Reported	$2.88B	(m)	(m)	(m)	43.43%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	$3.35B*	$2.45B	$901.00M*	$6.42B	52.22%*	$135.00M*	$3.37B*	$1.56B	(m)	$1.35B	$185.00M
2020-06-30	Reported	$3.25B*	$2.32B	$930.00M*	(m)	(m)	$158.00M*	$2.84B*	$1.49B	(m)	$1.29B	$227.00M
2020-03-31	Reported	$3.25B	(m)	(m)	(m)	52.78%	$142.00M	$2.13B	$1.51B	(m)	$1.32B	$195.00M
2019-12-31	Reported	$2.75B	(m)	(m)	(m)	44.38%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	$2.98B*	$2.48B	$508.00M*	(m)	(m)	$170.00M*	$3.38B*	$1.04B	(m)	$1.22B	$309.00M
2019-06-30	Reported	$3.18B*	$2.68B	$501.00M*	(m)	(m)	$144.00M*	$1.41B*	$1.01B	(m)	$1.26B	$385.00M
2019-03-31	Reported	$2.97B	(m)	(m)	(m)	53.39%	$116.00M	$1.84B	$1.05B	(m)	$1.15B	$322.00M
2018-12-31	Reported	$2.87B	(m)	(m)	(m)	46.10%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	$2.82B*	$2.32B	$501.00M*	(m)	(m)	$171.00M*	$3.27B*	$1.04B	(m)	$1.29B	$235.00M
2018-06-30	Reported	$3.32B*	$2.83B	$484.00M*	(m)	(m)	$187.00M*	$2.10B*	$1.02B	(m)	$1.35B	$351.00M
2018-03-31	Reported	$3.2B	(m)	(m)	(m)	57.56%	$155.00M	$2.73B	$944.00M	(m)	$1.13B	$308.00M
2017-12-31	Reported	$2.69B	(m)	(m)	(m)	46.43%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	$2.90B*	$2.44B	$464.00M*	(m)	(m)	$158.00M*	$3.45B*	$990.00M	(m)	$1.17B	$360.00M
2017-06-30	Reported	$3.22B*	$2.70B	$518.00M*	(m)	(m)	$185.00M*	$2.33B*	$1.02B	(m)	$1.21B	$391.00M
2017-03-31	Reported	$3.12B	(m)	(m)	(m)	57.01%	$168.00M	$2.38B	(m)	(m)	$1.06B	$389.00M
2016-12-31	Reported	$3.04B	(m)	(m)	(m)	51.03%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	$3.03B*	$2.53B	$503.00M*	(m)	(m)	$167.00M*	$2.66B*	(m)	(m)	$1.24B	$401.00M
2016-06-30	Reported	$2.90B*	$2.38B	$522.00M*	(m)	(m)	$188.00M*	$2.68B*	(m)	(m)	$1.29B	$334.00M
2016-03-31	Reported	$2.92B	(m)	(m)	(m)	52.89%	$156.00M	$1.92B	(m)	(m)	$1.20B	$358.00M
2015-12-31	Reported	$2.58B	(m)	(m)	(m)	46.51%	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	$2.86B*	$2.34B	$523.00M*	(m)	(m)	$138.00M*	$2.89B*	(m)	(m)	$1.24B	$329.00M
2015-06-30	Reported	$2.60B*	$2.08B	$519.00M*	(m)	(m)	$133.00M*	$3.28B*	(m)	(m)	$1.16B	$344.00M
2015-03-31	Reported	$2.55B	(m)	(m)	(m)	50.59%	$118.00M	$1.48B	(m)	(m)	$1.03B	$253.00M
2014-12-31	Reported	$1.98B	(m)	(m)	(m)	37.22%	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	$2.01B*	$1.47B	$543.00M*	(m)	(m)	$170.00M*	$2.74B*	(m)	(m)	$1.21B	$93.00M
2014-06-30	Reported	$2.41B*	$1.90B	$506.00M*	(m)	(m)	$173.00M*	$2.23B*	(m)	(m)	$1.14B	$211.00M
2014-03-31	Reported	$1.88B	(m)	(m)	(m)	41.63%	$172.00M	$1.14B	(m)	(m)	$1.02B	$131.00M
2013-12-31	Reported	$1.63B	(m)	(m)	(m)	32.55%	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	$1.98B*	$1.69B	$288.00M*	(m)	(m)	$175.00M*	$1.81B*	(m)	(m)	$1.25B	$135.00M
2013-06-30	Reported	$1.83B*	$1.55B	$277.00M*	(m)	(m)	$159.00M*	$1.60B*	(m)	(m)	$1.26B	$147.00M
2013-03-31	Reported	$1.72B	(m)	(m)	(m)	40.56%	$158.00M	$1.05B	(m)	(m)	$1.16B	-$91.00M
2012-12-31	Reported	$1.36B	(m)	(m)	(m)	30.78%	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	$1.71B*	$1.42B	$287.00M*	(m)	(m)	$173.00M*	$1.72B*	(m)	(m)	$1.13B	$156.00M
2012-06-30	Reported	$1.86B*	$1.59B	$269.00M*	(m)	(m)	$172.00M*	$2.38B*	(m)	(m)	$1.23B	$191.00M
2012-03-31	Reported	$1.74B	(m)	(m)	(m)	42.89%	$144.00M	$972.00M	(m)	(m)	$1.08B	$182.00M
2011-12-31	Reported	$1.42B	(m)	(m)	(m)	35.82%	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	$790.00M*	$525.00M	$265.00M*	(m)	(m)	$120.00M*	$969.00M*	(m)	(m)	$1.13B	$0.00
2011-06-30	Reported	$1.59B*	$1.33B	$261.00M*	(m)	(m)	$123.00M*	$1.54B*	(m)	(m)	$1.13B	$169.00M
2011-03-31	Reported	$1.57B	(m)	(m)	(m)	42.26%	$100.00M	$1.03B	(m)	(m)	$1.02B	$181.00M
2010-12-31	Reported	$1.33B	(m)	(m)	(m)	34.60%	(m)	(m)	(m)	(m)	(m)	(m)
2010-09-30	Reported	$1.73B*	$1.48B	$253.00M*	(m)	(m)	$127.00M*	$1.30B*	(m)	(m)	$957.00M	$198.00M
2010-06-30	Reported	$1.77B*	$1.52B	$251.00M*	(m)	(m)	$177.00M*	$1.56B*	(m)	(m)	$986.00M	$262.00M
2010-03-31	Reported	$1.73B	(m)	(m)	(m)	48.25%	$94.00M	$913.00M	(m)	(m)	$884.00M	$253.00M
2009-12-31	Reported	$1.38B	(m)	(m)	(m)	36.23%	(m)	(m)	(m)	(m)	(m)	(m)
2009-09-30	Reported	$1.88B*	$1.60B	$272.00M*	(m)	(m)	$130.00M*	$1.98B*	(m)	(m)	$932.00M	$154.00M
2009-06-30	Reported	$1.71B*	$1.46B	$253.00M*	(m)	(m)	$139.00M*	$1.68B*	(m)	(m)	$910.00M	$88.00M
2009-03-31	Reported	$1.59B	(m)	(m)	(m)	48.00%	$117.00M	$859.00M	(m)	(m)	$798.00M	$213.00M
2008-12-31	Reported	$1.41B	(m)	(m)	(m)	37.62%	(m)	(m)	(m)	(m)	(m)	(m)
2008-09-30	Reported	(m)	$1.48B	(m)	(m)	(m)	(m)	$1.39B*	(m)	(m)	$900.00M	$291.00M
2008-06-30	Reported	(m)	$1.18B	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$904.00M	$224.00M

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$14.25B	(m)	(m)	(m)	38.77%	$1.86B	$9.96B	$12.04B	(m)	$7.05B	$1.26B
2024-12-31	Reported	$12.85B	(m)	(m)	(m)	38.45%	$1.10B	$11.49B	$12.86B	(m)	$7.10B	$519.00M
2023-12-31	Reported	$11.97B	(m)	(m)	(m)	42.45%	$1.11B	$8.47B	$8.45B	(m)	$6.18B	$1.14B
2022-12-31	Reported	$12.98B	(m)	(m)	(m)	49.32%	$936.00M	$9.72B	$6.41B	(m)	$5.41B	$794.00M
2021-12-31	Reported	$11.04B	(m)	(m)	(m)	42.48%	$880.00M	$9.26B	$6.45B	(m)	$5.37B	$808.00M
2020-12-31	Reported	$12.74B	(m)	(m)	(m)	50.11%	$608.00M	$10.50B	$6.16B	(m)	$5.73B	$869.00M
2019-12-31	Reported	$11.88B	(m)	(m)	(m)	50.85%	$618.00M	$9.15B	$4.36B	(m)	$5.15B	$1.30B
2018-12-31	Reported	$12.21B	(m)	(m)	(m)	51.41%	$738.00M	$11.30B	$4.10B	(m)	$5.33B	$1.15B
2017-12-31	Reported	$11.93B	(m)	(m)	(m)	52.20%	$664.00M	$11.18B	$4.07B	(m)	$4.87B	$7.62B
2016-12-31	Reported	$11.9B	(m)	(m)	(m)	51.76%	$738.00M	$10.35B	$4.16B	(m)	$5.06B	$1.44B
2015-12-31	Reported	$10.58B	(m)	(m)	(m)	48.83%	$594.00M	$9.73B	(m)	(m)	$4.85B	$1.04B
2014-12-31	Reported	$8.28B	(m)	(m)	(m)	41.28%	$718.00M	$8.95B	(m)	(m)	$4.70B	$427.00M
2013-12-31	Reported	$7.15B	(m)	(m)	(m)	38.30%	$693.00M	$6.53B	(m)	(m)	$5.18B	$184.00M
2012-12-31	Reported	$6.67B	(m)	(m)	(m)	38.60%	$689.00M	$5.88B	(m)	(m)	$4.81B	$664.00M
2011-12-31	Reported	$5.37B	(m)	(m)	(m)	34.48%	$567.00M	$5.12B	(m)	(m)	$4.50B	$467.00M
2010-12-31	Reported	$6.56B	(m)	(m)	(m)	43.59%	$580.00M	$5.79B	(m)	(m)	$3.98B	$690.00M
2009-12-31	Reported	$6.56B	(m)	(m)	(m)	44.77%	$530.00M	$6.34B	(m)	(m)	$3.82B	$599.00M
2008-12-31	Reported	$6.29B	(m)	(m)	(m)	41.90%	$672.00M	$5.99B	(m)	(m)	$3.79B	$963.00M
2007-12-31	Reported	$5.18B	(m)	(m)	(m)	35.08%	$1.27B	$5.40B	(m)	(m)	$3.36B	$715.00M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
GILEAD SCIENCES, INC. (GILD)	United States	$185.522B	-48.37
Moderna, Inc. (MRNA)	United States	$77.819B	-8.86
Revolution Medicines, Inc. (RVMD)	United States	$42.805B	-22.69
BIOGEN INC. (BIIB)	United States	$33.427B	19.60
EXELIXIS, INC. (EXEL)	United States	$14.358B	16.15
NEUROCRINE BIOSCIENCES INC (NBIX)	United States	$14.131B	24.25
HALOZYME THERAPEUTICS, INC. (HALO)	United States	$13.083B	21.59
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31